Cell and Gene Therapies – Global Clinical Trial Landscape (2024)

The landscape of cell and gene therapy is advancing rapidly, revolutionizing healthcare by offering novel treatments for cancer, rare genetic conditions, and hematological diseases. These therapies, which modify the genetic structure of cells to correct or replace defective genes, are gaining global traction. CAR-T therapies are among the most promising innovations with CAR-NK therapies emerging as well with the aim of providing scalable, off-the-shelf solutions, that further expand the range of personalized treatments. Regions such as Asia-Pacific are leading the charge, with China at the forefront of CAR-T clinical trials. North America and Europe continue to make strides in research and regulatory frameworks, enabling faster approvals and collaborations. Advances in AI are also transforming the field, aiding in therapeutic design and patient-specific solutions.

This progress brings both challenges and opportunities, particularly around high costs and commercialization. However, with accelerating investment, regulatory support, and technological breakthroughs, cell and gene therapies are set to reshape modern medicine and patient care.